Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... Some recovery was aided by the ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Gilead Sciences, seeing a 22% boost ... bolstered by the still high demand for their weight-loss and diabetes drugs, which ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter ... due in part to a $1.75 billion ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.